CSF neurofilament light chain (NfL) serves as a dynamic biomarker for real-time monitoring of axonal damage to guide astrocyte-derived extracellular vesicle (AEV) delivery of lncRNA-0021 in Alzheimer's disease. Unlike static p-tau217 measurements, CSF NfL levels fluctuate with acute neuronal injury episodes, enabling responsive therapeutic dosing that matches the kinetics of ongoing neurodegeneration. Elevated CSF NfL (>2000 pg/mL) triggers immediate AEV-lncRNA-0021 deployment, which crosses the
CSF p-tau217 serves as a predictive biomarker for optimal lncRNA-0021 (via MSC exosome) therapeutic intervention timing, with the greatest efficacy observed when plasma p-tau217 levels are elevated but before significant neuronal loss. Plasma p-tau217 demonstrates higher specificity to AD pathology compared to p-tau181 and rises earlier in the disease course, enabling earlier detection windows for therapeutic intervention. The p-tau217-guided dosing window framework aligns with the disease-modif
Verdict Summary
1/10
dimensions won
CSF Neurofilament Light Chain-Guided Ast
10/10
dimensions won
Plasma p-tau217-Triggered Exosome Dosing
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.67
0.75
Evidence
0.36
0.70
Novelty
0.50
0.50
Feasibility
0.33
0.85
Impact
0.55
0.65
Druggability
0.50
0.80
Safety
0.50
0.75
Competition
0.45
0.55
Data
0.35
0.75
Reproducible
0.58
0.75
Score Breakdown
Dimension
CSF Neurofilament Light Chain-
Plasma p-tau217-Triggered Exos
Mechanistic
0.670
0.750
Evidence
0.360
0.700
Novelty
0.500
0.500
Feasibility
0.330
0.850
Impact
0.550
0.650
Druggability
0.500
0.800
Safety
0.500
0.750
Competition
0.450
0.550
Data
0.350
0.750
Reproducible
0.580
0.750
Evidence
CSF Neurofilament Light Chain-Guided Astrocyte-Derived Extra